Kentucky’s Horses and Hope is going international. Champion equestrian and Horses and Hope Pink Stable member Misdee Wrigley Miller will spread the message of breast cancer awareness as she competes next week in two European Equestrian World Cup qualifying events.

In 2008, the office of Kentucky First Lady Jane Beshear partnered with the Kentucky Cancer Program to create Horses and Hope. The program’s mission is to increase breast cancer awareness, education, screening and treatment referral among Kentucky’s horse industry workers and their families.

The University of Louisville and the University of Kentucky operate the Kentucky Cancer Program and staff Horses and Hope programs and events. UofL’s James Graham Brown Cancer Center, a part of KentuckyOne Health, manages the Kentucky Cancer Program for the western half of the Commonwealth.

On Thursday, July 3, Miller will compete in CAI3* horse driving competitions in Lähden and Riesenbeck, Germany, in the four-in-hand combined driving competition. Both competitions are FEI World Equestrian Game qualifying events. While there, she will spread awareness about the importance of breast cancer screening, early detection and education through the Horses and Hope program—sharing the program’s best practices and encouraging international participation.

Since 2009, she has served as a member of the Pink Stable, a committee of Kentucky horse owners, riders, trainers, farm owners and jockeys that support the Horses and Hope initiative.

“I have been grateful to serve as member of First Lady Jane Beshear's Horses and Hope Pink Stable committee, and even more honored to serve as an ambassador for this important initiative as I compete in Europe,” Miller said. “Women are traditionally care givers, especially so in the horse business; often they take care of their horses before they think of themselves. I have friends and family who have been touched by breast cancer, so I am aware of the importance of early detection. If I accomplish anything here, I want every woman, especially those with high risk, who hear my message to practice self-examination and get screened.”

Miller is a fourth-generation horsewoman and has been involved in the horse business her entire life. She is an accomplished rider and has competed as a United States team member twice in the FEI Pair Horse World Championships, was the 2013 USEF National Champion in Pairs and the 2014 USEF Reserve National Champion in 4-In Hands.

Horses and Hopehas hosted several breast cancer race days at Kentucky racetracks in the past six years, reaching nearly 1 million race track and horse show fans and educating nearly 16,000 equine employees. The program has screened close to 700 workers and detected breast cancer in two individuals, both of whom have received treatment.

The next Horses and Hope Race Day will be at Ellis Park in Henderson, Ky., on Aug. 2. For more information about Horses and Hope and all upcoming events, please visit www.horsesandhope.org.

For more information on breast cancer, please contact the Kentucky Cancer Program at UofL at http://kycancerprogram.org/kcp-west/.

A national publication for health care executives and managers has ranked the University of Louisville’s College of Business as one of the top business graduate schools for physician-executives.

UofL appears on a list Modern Healthcare compiled in May of the top graduate schools awarding advanced degrees in health care business administration in 2013-14. The ranking is based on how many full-time students are pursuing the degree at each school.

UofL placed at the 20^th spot with 45 students, just under Yale School of Management’s 48 students. Rice University’s graduate business school topped the list with 231 students.

UofL’s business school has offered an MBA degree with a health care focus since 2011. Students in the 20-month program take weekend courses preparing them for executive positions in hospital administration, senior care, health insurance, biomedicine and related areas.

For more details, see http://business.louisville.edu/wptest/images/Ranked20.pdf

Telemedicine is an effective strategy to screen for the potentially blinding disease known as retinopathy of prematurity (ROP), according to a study funded by the National Eye Institute (NEI). The investigators say that the approach, if adopted broadly, could help ease the strain on hospitals with limited access to ophthalmologists and lead to better care for infants in underserved areas of the country. NEI is a part of the National Institutes of Health.

The telemedicine strategy consisted of electronically sending photos of babies’ eyes to a distant image reading center for evaluation. Staff at the image reading center, who were trained to recognize signs of severe ROP, identified whether infants should be referred to an ophthalmologist for evaluation and potential treatment. The study tested how accurately the telemedicine approach reproduced the conclusions of ophthalmologists who examined the babies onsite.

“This study provides validation for a telemedicine approach to ROP screening and could help save thousands of infants from going blind,” said Graham E. Quinn, M.D., professor of ophthalmology at the Children's Hospital of Philadelphia and the lead investigator for the study, which is reported today in JAMA Ophthalmology.

The study was conducted by the e-ROP Cooperative Group, a collaboration that includes 12 facilities in the United States and one in Canada. The University of Louisville was the only site in Kentucky among the collaborative group. In addition to UofL, study sites were Johns Hopkins University, Boston Children’s Hospital, Vanderbilt University, Children’s Hospital of Philadelphia, Nationwide Children’s Hospital/Ohio State University Hospital, Duke University, University of Minnesota, University of Oklahoma, University of Pennsylvania, University of Texas Health Science Center at San Antonio, University of Utah and Hospital of the Foothills Medical Center (Calgary, Canada).

Some degree of ROP appears in more than half of all infants born at 30 weeks pregnancy or younger—a full-term pregnancy is 40 weeks—but only about 5 to 8 percent of cases become severe enough to require treatment. In ROP, blood vessels in the tissue in the back of the eye called the retina begin to grow abnormally, which can lead to scarring and detachment of the retina. Treatment involves destroying the abnormal blood vessels with lasers or freezing them using a technique called cryoablation. Early diagnosis and prompt treatment is the best prevention for vision loss from ROP, which is why the American Academy of Ophthalmology recommends routine screening for all babies who are born at gestational age 30 weeks or younger or who weigh less than 3.3 pounds at birth.

The study evaluated telemedicine for ROP screening during the usual care of 1,257 premature infants who were born, on average, 13 weeks early. About every nine days, each infant underwent screening by an ophthalmologist, who assessed whether referral for treatment was warranted. Those who were referred were designated as having referral-warranted ROP (RW-ROP). Either immediately before or after the exam, a non-physician staff member in the neonatal intensive care unit (NICU) took images of the infant’s retinas and uploaded them to a secure server at the University of Oklahoma, Oklahoma City. Trained non-physician image readers at the University of Pennsylvania, Philadelphia, then downloaded the photos, independently evaluated them following a standard protocol, and reported the presence or absence of RW-ROP.

Through the telemedicine approach, non-physician image readers correctly identified 90 percent of the infants deemed to have RW-ROP based on examination by an ophthalmologist. And they were correct 87 percent of the time when presented with images from infants who lacked RW-ROP. The examining ophthalmologists documented 244 infants with RW-ROP on exam. After referral, 162 infants were treated. Of these, non-physician image readers identified RW-ROP in all but three infants (98 percent).

“This is the first large clinical investigation of telemedicine to test the ability of non-physicians to recognize ROP at high risk of causing vision loss,” said Eleanor Schron, Ph.D., group leader of NEI Clinical Applications. “The results suggest that telemedicine could improve detection and treatment of ROP for millions of at-risk babies worldwide who lack immediate in-person access to an ophthalmologist,” she said.

About 450,000, or 12 percent,  of the 3.9 million babies born each year in the United States are premature. The number of preterm infants who survive has surged in middle income countries in Latin America, Asia and Eastern Europe. In these parts of the world, rates of childhood blindness from ROP are estimated at 15 to 30 percent—compared to 13 percent in the United States.

One advantage of telemedicine ROP screening is that it can be done more frequently than screening by an ophthalmologist. “It’s much easier to examine the retina when not dealing with a wiggling baby,” said Quinn said. “If a baby is too fussy or otherwise unavailable when the ophthalmologist visits the NICU, the exam may be delayed until the ophthalmologist returns—sometimes up to a week later.”

Weekly ROP screening—or even more frequently for high-risk babies—is a realistic goal for telemedicine and could help catch all cases needing treatment, according to the report. In the study, imaging was restricted to occasions when an ophthalmologist examined the baby. In practice, hospital staff could implement an imaging schedule based on the baby’s weight, age at birth and other risk factors. “With telemedicine, NICU staff can take photos at the convenience of the baby,” Quinn said.

Telemedicine for evaluating ROP offers several other advantages:

• Telemedicine may help detect RW-ROP earlier. In the study, about 43 percent of advanced ROP cases were identified by telemedicine before they were detected by an ophthalmologist—on average, about 15 days earlier.
• Telemedicine could save babies and their families the hardship and hazards of being unnecessarily transferred to larger nurseries with greater resources and more on-site ophthalmologists. “Telemedicine potentially gives every hospital access to excellent ROP screening,” Dr. Quinn said.
• Telemedicine might also bring down the costs of routine ROP screening by reducing the demands on ophthalmologists, whose time is better allocated to babies who need their attention and expertise. In a separate analysis, the study found that non-physicians and physicians had similar success in assessing photos for RW-ROP. Three physicians evaluated image sets from a random sample of 200 babies (100 with RW-ROP based on the eye exam findings; 100 without) using the standard grading protocol. On average, the physicians correctly identified about 86 percent of RW-ROP cases; the non-physicians were correct 91 percent of the time. The physicians correctly identified about 57 percent of babies without RW-ROP; non-physicians were correct 73 percent of the time.

The cost of establishing a telemedicine ROP screening program includes acquisition of a special camera for taking pictures of the retina, training of NICU personnel to take and transmit quality photos, and establishment and maintenance of an image reading center. “As we move along this road, advances in imaging and grading of images may streamline the process even more,” Dr. Quinn said.

For more information about ROP, visit http://www.nei.nih.gov/health/rop/.

To view a video about e-ROP, visit the NEI YouTube channel at http://youtu.be/7l_CqjV3NMA.

Andrea L. Behrman, Ph.D., was selected to give the Maley Lecture at the American Physical Therapy Association (APTA) in Charlotte, N.C., on June 13. The lecture honors a physical therapist that has made distinguished contributions to the profession of physical therapy in clinical practice.

Behrman is a professor in the Department of Neurological Surgery and Kentucky Spinal Cord Injury Research Center at the University of Louisville and is currently examining neuromuscular recovery in children with spinal cord injuries via both research and clinical practice. She also is a licensed physical therapist and is a Fellow of the American Physical Therapy Association.

Behrman’s lecture was titled, “I never thought that I would need to child-proof my home!” and focused on a paradigm shift for rehabilitation from the traditional view that “paralysis cannot be resolved” to an evidence-based physiological perspective that, with training, “paralysis can be resolved” and recovery is possible – to what degree has yet to be determined. As the mother whose comments inspired the lecture’s title said, “after locomotor training, my child became so mobile that I needed to child-proof my home” – something she never thought she would need to be concerned about.

Researchers have demonstrated that the spinal cord is in fact smart and that it can learn, Behrman said. By providing specific sensory input via intense training, therapists can activate the spinal circuitry and the neuromuscular system below and across the level of the injury.

Using a method known as “activity-based locomotor training,” therapists provide specific sensory information while patients are standing and walking on a treadmill with partial body weight support. Trainers also provide manual cues to promote muscle activation. Behrman demonstrated the benefits of locomotor training for developing trunk control and stepping in children who suffered a spinal cord injury when they were as young as 5 months and were paralyzed for nearly three years.

As director of the University of Louisville Kosair Charities Center for Pediatric Neurorecovery, Behrman and her fellow researchers and clinical partners work to change outcomes for children recovering from paralysis while undergoing locomotor training.

More information about Behrman’s lecture and work at UofL is available on the American Physical Therapy Association website.

Mariusz Ratajczak, M.D., Ph.D., D.Sci., has been selected to receive the prestigious Karl Landsteiner Prize from the German Society for Transfusion Medicine and Immunohematology. Ratajczak holds the Henry M. and Stella M. Hoenig Endowed Chair at the University of Louisville.

The Landsteiner Prize is given by the society to a doctor for outstanding achievements and research in the fields of transfusion and/or immunology. The prize is named after Karl Landsteiner, an Austrian biologist and physician. In addition to distinguishing the main blood groups, Landsteiner also discovered polio along with several other researchers and received the Nobel Prize in Physiology or Medicine in 1930. Landsteiner is recognized as the father of transfusion medicine. Previous recipients of the Karl Landsteiner Prize include Nobel Prize laureate Rolf Zinkernagel (Basel), Karl Blume (Seattle) and Stephanie Dimmeler (Frankfurt).

Ratajczak was honored for his outstanding achievements in the characterization of mechanisms involved in the mobilization of hematopoietic stem cells and the discovery of very small embryonic like stem cells in the adult tissue.

An internationally known specialist in the field of adult stem cell biology, his 2005 discovery of embryonic-like stem cells in adult bone marrow has potential to revolutionize the field of regenerative medicine. The discovery may lead to new treatments for heart disease, eye disease, diabetes and neurodegenerative disorders, as well as provide insight into the development of many forms of leukemia.

In addition to his endowed position, Ratajczak is a professor in the Department of Medicine and the director of the Developmental Biology Research Program and of the Research Flow and Sorting Core Facility at the University of Louisville's James Graham Brown Cancer Center.

In addition to receiving the Karl Landsteiner Prize, Ratajczak has also been invited to deliver an opening lecture on Sept. 9 during the society’s annual meeting in Dresden, Germany.

Researchers at the University of Louisville have uncovered a cadre of small molecules that tell certain proteins to kill lung cancer cells. The team, led by Chi Li, Ph.D., assistant professor of medicine, published its finding in the April 2014 issue of Molecular and Cellular Biology.

One of the characteristics of lung cancer is the dysregulation of apoptosis, or regulated cell death. Cancer cells are able to survive in the unnatural state.

Proteins from the Bcl-2 family are major regulators of apoptosis. One of them, Bax, sometimes becomes erratic and loses its ability to maintain its killer function, which leads to lung tumor development. The researchers realized that this meant Bax potentially could be part of the cure as well.

The researchers used virtual screening in their study, a process where they ran through a computer program all the possible combinations of molecules that could bind with the Bax proteins to find the best combination. After trying more than 10 million molecules, they found the right one. This Bax-activating small molecule compound kills lung cancer cells as well as inhibits the growth of lung tumors transplanted into mice.

The scientific finding of Li and his team showed it is possible to identify small molecules capable of binding and activating Bax proteins that in turn induce apoptosis in cancerous cells. In the study, published in Molecular and Cellular Biology in April of 2014, Li and his team were able to specifically induce tumor cell death while avoiding normal cell death.

The compound also shows synergy with the widely used chemotherapeutic drug carboplatin. This means that the potential application for this compound in cancer treatment is very broad.

The scientific discovery could form the basis for advanced therapeutic agents for cancer in patients, specifically lung cancer, which is especially prevalent in Kentucky.

The high mortality rate of lung cancer is partially attributed to ineffective therapeutic treatments. This makes it very important for scientists to develop new chemotherapeutic drugs for lung cancer.

Li says it could pave the way for new treatment for other types of cancer as well. “Lung cancer is a really big issue for us. We have a large mortality rate, and that’s one of the reasons we wanted to go after lung cancer,” he said. “We are in the process of trying to expand the application of our discovery onto different types of cancer.”

Li and his team will have the opportunity for that expansion very soon. The National Institutes of Health recently awarded them a grant of $1.5 million to continue their groundbreaking research.

Attention, shopaholics: Here’s your chance to be among the very first to shop The Outlet Shoppes of the Bluegrass.

The Outlet Shoppes of the Bluegrass is teaming with the University of Louisville’s James Graham Brown Cancer Center for an Opening Night VIP Preview from 6-9 p.m., Wednesday, July 30, the evening before the facility opens to the general public.

Patrons will be able to get the jump on the rest of Kentuckiana in shopping at choice retail outlets such as Coach, Brook Brothers, Saks Fifth Avenue Off 5^th, Michael Kors, J Crew, Banana Republic, Nike, Talbots, Under Armour and more. They also will receive a free coupon book with over $300 in savings at many of the 80-plus retailers that make up The Outlet Shoppes of the Bluegrass.

Cost is $50 per person with 100 percent of the proceeds going to the James Graham Brown Cancer Center, the only cancer center in the region to use a unified approach to cancer care, with multidisciplinary teams of physicians working together to guide patients through diagnosis, treatment and recovery.

“We are thrilled to partner with The Outlet Shoppes of the Bluegrass,” Michael Neumann, executive director of development for the cancer center, said. “The pairing of Kentucky’s new premier shopping center with the region’s premier cancer research and treatment center is a great fit.”

Only 3,000 tickets to the event are available and are expected to go fast, Neumann said. Tickets are sold online only at www.shoppingforacure.org. Up to 10 tickets may be purchased per transaction.

The Veritas Curat Foundation is handling ticket sales on behalf of the cancer center, and receipts will be provided via email. The email receipt serves as the ticket to the event, and to be admitted, ticket buyers must bring both a printout of the email receipt and identification that matches the name on the ticket.

A silent auction of packages donated by Shoppes retailers also will be held the night of the VIP Preview, Neumann said. Items up for auction will be posted in advance on the website starting July 28, and online bidding will be available until July 30. On-site bidding on the night of the event will be conducted via smartphone only, he added.

The Outlet Shoppes of the Bluegrass is located at Exit 28 on Interstate 64. For additional information on the Opening Night VIP Preview or the James Graham Brown Cancer Center, contact Neumann at 502-562-4642.

Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, announced June 4 that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials. The U.S. Food and Drug Administration approved Phase 1 dose escalation study is evaluating the safety, tolerability and anti-tumor activity of PFK-158 in cancer patients with solid tumors such as melanoma, lung, colon, breast and pancreatic cancer.

PFK-158 is the first 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) inhibitor to undergo clinical trial testing in cancer patients. The target, PFKFB3, is activated by oncogenes and the low oxygen state in cancers, stimulates glucose metabolism and is required for the growth of cancer cells as tumors in mice. PFK-158, which has been licensed by ACT from the James Graham Brown Cancer Center at the University of Louisville, inhibits the substrate binding domain of PFKFB3 causing a marked reduction in the glucose uptake and growth of multiple cancer types in mice.

PFK-158 human clinical trials began recruiting patients in May with the first clinical trial site located at the James Graham Brown Cancer Center, a part of KentuckyOne Health. Within weeks of opening the first clinical trial site, ACT was able to open the second clinical trial site at Georgetown University Medical Center in Washington, also in May.

According to Jason A. Chesney, M.D., Ph.D., deputy director of the Brown Cancer Center and a global thought leader and researcher in cancer metabolism, “PFK-158 is not only a first-in-class cancer drug but also the first to target glucose metabolism by inhibiting PFKFB3. This unique mechanism of action has resulted in efficacy against a broad spectrum of human cancers caused by common mutations as well as synergy with targeted agents that are FDA approved for several cancer types.

“As a researcher, it is incredibly rewarding to witness your group's studies move into clinical trials and potentially save the lives of cancer patients,” Chesney said.

“This is a significant milestone for ACT and it supports our dedication to develop significant treatment advancements for cancer patients with first-in-class, potential breakthrough therapeutics like PFK-158,” said Randall B. Riggs, president & CEO of ACT.

About Advanced Cancer Therapeutics (ACT):

ACT is a privately held company dedicated to advancing novel therapeutics for the prevention and treatment of cancer. ACT has successfully established a unique and innovative business model with the University of Louisville’s James Graham Brown Cancer Center whereby ACT is able to obtain exclusive worldwide licenses to novel cancer therapeutics discovered at Brown Cancer Center under preset business terms. ACT then fast-tracks these discoveries, including the selection process for partnership, commercialization and manufacture, to the pharmaceutical industry, and ultimately to the patients who need them. Led by Donald M. Miller, M.D., Ph.D., the Brown Cancer Center employs more than 50 scientists focused on the discovery and advancement of breakthrough cancer therapeutics for patients suffering from cancer. For more information, please visit www.advancedcancertherapeutics.com.

About the James Graham Brown Cancer Center:

The James Graham Brown Cancer Center is a key component of the University of Louisville Health Sciences Center. As part of the region's leading academic, research and teaching health center, the cancer center provides the latest medical advances to patients, often long before they become available in non-teaching settings. The JGBCC is a part of KentuckyOne Health and is affiliated with the Kentucky Cancer Program. It is the only cancer center in the region to use a unified approach to cancer care, with multidisciplinary teams of physicians working together to guide patients through diagnosis, treatment and recovery. For more information, visit our web site, www.browncancercenter.org.

UofL Geriatrics in the Department of Family and Geriatric Medicine at the University of Louisville is calling for nominations for the fourth annual Gold Standard Award for Optimal Aging.

The deadline to submit nominations is 5 p.m., July 15. The award will be presented Sept. 25 at the Annual UofL Geriatrics Gold Standard Award for Optimal Aging Luncheon at the Crowne Plaza Hotel, 830 Phillips Lane.

The Gold Standard Award for Optimal Aging is presented to someone 85 years old or older as of Oct. 1 who is an outstanding model for optimal aging in all areas of life.

“We are seeking people 85-plus who are making the most of whatever their later years bring and who continue to demonstrate great zest for life,” said Christian Davis Furman, M.D., vice chair for geriatric medicine. “The award is presented for optimal aging across the full spectrum of physical health, mental health, social health and spiritual health.”

The nomination process includes submitting information on the nomination form that describes why the nominee qualifies for the award. Nomination forms and information about the luncheon can be found online or obtained by calling (502) 588-4260 or emailing UofLGeriatrics@louisville.edu.

Experts in the use of comprehensive geriatric assessment for hospitalized elders and immunizations in older adults, and the author of the 2012 Beers Criteria – a guide to medication use in elders – will be featured at the 14^th Annual University of Louisville Geriatrics Healthcare Symposium.

The conference will be held Friday, Sept. 19, at the Seelbach Hilton Hotel, 500 S. Fourth St. in Downtown Louisville.

The conference is sponsored by the Division of Geriatrics in the Department of Family and Geriatric Medicine at the University of Louisville and provides information on the latest research and best practices in care for people age 65 and older. Plenary speakers include:

• Michael Malone, M.D., Center for Senior Health & Longevity, Aurora Sinai Medical Center, Milwaukee, addressing the acute care of elderly hospitalized patients.
• Kenneth Schmader, M.D., Geriatrics Division Chief, Duke University School of Medicine, Durham, N.C., providing information on immunizations for elders
• Todd Semla, Pharm.D., Feinberg School of Medicine, Northwestern University, Chicago, speaking on polypharmacy, the overuse or misuse of medications in older adults

Other sessions will be held on POLST: Physician’s Orders for Life, disease screening and prevention, caregiver burnout, injury prevention, exercise, elder abuse, dementia and enhancing independence in the older adult.

The conference is open to health care professionals and students and the public alike. CE credit will be available for physicians, nurses, social workers and other professionals working in the field of geriatrics.

For details, contact the UofL Division of Geriatrics, 502-852-3480 or awburk02@louisville.edu.

Benefactors of a fund to support patients at the James Graham Brown Cancer Center at the University of Louisville are sponsoring their second annual sand volleyball event to raise money for the fund.

In 2013, Alex and Tommy Gift established the Mary Jane Gift Quality of Life Fund at the cancer center in honor of their late mother. The fund helps patients and their families enjoy life while facing a cancer diagnosis.

To benefit the fund, the Gifts are sponsoring The Second Annual Spike It to Cancer Sand Volleyball Tournament at Baxter Jack’s sand volleyball complex, 427 Baxter Ave. on Saturday, June 7. Registration will be held from 1-2:30 p.m., and games will begin at 3 p.m.

Admission is $20 per person. Payment by cash or check will be accepted at the door, or participants can pay by credit card at the cancer center’s secure online link.

“All proceeds from this event go to the Mary Jane Gift Quality of Life Fund that pays for extras provided to our patients and caregivers,” Michael Neumann, executive director of development, said. “Additionally, The Brewery on Baxter Avenue directly across the street from Baxter Jack’s has agreed to donate a portion of all food and beverage sales to us during the event.

“These gifts go a long way in bringing cheer to our patients and their families. For example, the fund provided Thanksgiving turkeys to many of our patients and their families last November. Also, one of our physicians, Dr. Cesar Rodriguez, used funds raised by the 2013 Spike It to Cancer to give picnic baskets to 26 patients on Easter morning.”

For additional details, contact Neumann at 502-562-4642.

Promising early preclinical research currently underway at the University of Louisville could lead to the elimination of a second surgery now commonly needed after retinal surgery.

Shlomit Schaal, M.D., Ph.D., associate professor, Department of Ophthalmology and Visual Sciences, and director of Retina, the Retina Fellowship Program in Vitreo-Retinal Diseases and Surgery and the Diabetic Retinopathy Service, Kentucky Lions Eye Center, is working with Martin O’Toole, Ph.D., assistant professor, Department of Bioengineering, on the project which is funded by the Coulter Translational Research Partnership at UofL.

The two are studying a new way for patients undergoing retinal surgery – known as “vitrectomy” – to avoid the need to have subsequent surgery to remove cataracts that develop. During vitrectomy surgery, vitreous gel is removed from the eye; it is this gel that protects the natural crystalline lens from damage caused by free radicals of oxygen.

With the gel loss during surgery, free radicals are diffused onto the lens and cause cataracts, and almost all patients undergoing vitrectomy surgery then are forced to undergo a second surgery to remove the cataracts.

Schaal and O’Toole have developed an artificial gel that is biocompatible to the vitreous gel present in the eye. Using animal models, Schaal has successfully used the biocompatible gel to create an oxygen barrier next to the lens during retinal vitrectomy surgery.

“The biocompatible gel appears to be working as well as the eye’s natural vitreous gel in blocking oxygen damage to the natural lens,” Schaal said.

The team hopes to be able to move the research into clinical trials within the next year. “The funding we’ve received from the UofL-Coulter Partnership has been invaluable in enabling us to prove our concept thus far,” Schaal said. “We are excited at the prospect of one day being able to help patients avoid the burden of cataract surgery after retinal surgery.”

The five-year, $5 million Coulter Translational Research Partnership in Bioengineering grant awarded in 2011 to UofL fosters the translation of research through successful collaboration between engineers and clinicians, supporting promising technologies.  The partnership funds promising projects in order to move innovative technologies to clinical application with the ultimate goal of accelerating the introduction of new technologies to improve the treatment and diagnosis of disease or reduce health care costs.

LOUISVILLE, Ky. – Noting the significant progress in drug and vaccine development over the past three years, the Leona M. and Harry B. Helmsley Charitable Trust, has provided a three-year, $5.5 million grant to the James Graham Brown Cancer Center at the University of Louisville to develop new treatments and vaccines for various forms of cancer.

“Seven years ago, we partnered with Owensboro Health to explore the novel idea of plant-based pharmaceuticals and vaccines in the treatment and prevention of cancer,” said Dr. James R. Ramsey, president of the University of Louisville. “Our team showed enough promise that the Helmsley Charitable Trust provided more than $3 million in research support in 2010. Today’s grant, with Dr. Donald Miller, director of the James Graham Brown Cancer Center, as the principal investigator, demonstrates the confidence the leaders of the trust have in the work that is being accomplished. We are extremely grateful to the trust for its support and we look forward to further opportunities to partner.”

The new funding will help UofL researchers move into clinical trials vaccines for cervical and colon cancer. Additionally, researchers will further develop plant-based drug delivery systems to allow for higher concentrations of anticancer drugs to be transported directly to human tumors, as well as to increase a tumor’s sensitivity to anticancer treatment. The plants involved in the research range from tobacco to soybeans to colored berries.

“The work of Dr. Miller and his team has the potential to significantly impact health around the world,” said John Codey, a trustee with the Helmsley Charitable Trust. “They are focusing on finding much less expensive methods for delivering vaccines and medications so that these treatments are accessible to even the poorest of countries. We are pleased to continue to support efforts that have the potential to relieve suffering for a significant segment of people around the world.”

The Helmsley Charitable Trust also has funded research at UofL focused on helping people with spinal cord injuries regain function. To date, the Helmsley Charitable Trust has provided UofL with nearly $15 million in research funding.

“Federal funding for research continues to be more and more competitive, with fewer researchers receiving funds each year,” said Dr. David L. Dunn, executive vice president for health affairs at UofL. “The resources the Helmsley Charitable Trust provides enables our internationally renowned researchers to continue with their groundbreaking work that has the potential to transform the lives of people worldwide. It is through these significant partnerships that innovative health care approaches are possible.”

“Owensboro Health’s cancer research partnership with the University of Louisville has allowed us to help lead the charge with groundbreaking projects in the fight against cancer. This grant has been key in allowing us to work toward taking solutions from the laboratory bench to the patient bedside,” said Philip Patterson, president and CEO of Owensboro Health. “Since its creation in 2007, the team at the Owensboro Cancer Research Program at our Mitchell Memorial Cancer Center has made tremendous strides. We are grateful for the renewed support from the Helmsley Charitable Trust.”

Under Miller’s leadership, researchers will move an oral cervical cancer vaccine from preclinical trials into pre-investigational new drug studies. These studies reduce the amount of time it takes to move a vaccine from the laboratory to use in people. The vaccine uses a specific protein (L2 minor capsid) to create a broad response to attack HPV, the virus responsible for the vast majority of cervical cancer, and should be ready to enter clinical trials by early 2015. This project is being led by Dr. Kenneth Palmer.

A second cervical cancer vaccine is being developed by two researchers who were part of the team that created the world’s first cervical cancer vaccine. Drs. Bennett Jenson and Shin-Je Ghim are working on a vaccine that is biosimilar to the original vaccine, but produced in tobacco plants. This effort also will enter into the pre-IND phase over the next two years.

Drs. Nobuyuki Matoba and Palmer are developing an oral cholera vaccine that may prove to be a way to prevent colon cancer. The gastrointestinal issues associated with cholera create a favorable environment for the development of colon cancer, thus, preventing cholera can also prevent colon cancer. The goal is for this vaccine to enter clinical trials in late 2014.

For several years, Dr. Huang-Ge Zhang has been exploring the anticancer properties of tiny particles called plant exosomes. Animal studies suggest that exosomes may be able to play a role in the treatment or prevention of colon, breast and lung cancer. Zhang was the first to demonstrate that exosomes existed in plants and plans to demonstrate that they could be used to deliver higher concentrations of anticancer drugs directly to human tumors.

Dr. Ramesh Gupta has uncovered that certain compounds within colored berries increase the anticancer effect of chemotherapy drugs. This has the potential to enable smaller amounts of the drugs to be used, but with the same or more beneficial effects.

“Our goal is to cure cancer in people, not in mice,” Miller said. “The Owensboro Cancer Research Program is a tremendous tool for reaching that goal, not just locally or regionally, but worldwide. Through plant-based pharmaceuticals, we will be able to provide low-cost vaccines and anticancer medications that make them accessible to even the poorest of nations. To have an organization like the Helmsley Charitable Trust partner with us will enable us to move toward our goal at a much quicker pace.”

UofL’s comprehensive campaign is scheduled to wrap up June 30 after already surpassing its $1 billion goal. Charting our Course formally launched in 2010 with the funds raised designated for academic support, scholarships and programs for students; faculty recruitment, research and professional development; infrastructure enhancements and upkeep of athletic facilities; and support of the university's academic units and libraries. More than 75,000 donors throughout the world have invested in the future of the University of Louisville. 

About the Helmsley Charitable Trust

The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting effective nonprofits in health, place-based initiatives, and education and human services.Since 2008, when the Trust began its active grantmaking, it has committed more than $1 billion to a wide range of charitable organizations.For more information on the Trust and its programs, visit www.helmsleytrust.org.

An institute at the University of Louisville and the physician-director of UofL’s James Graham Brown Cancer Center won two MediStar awards presented Tuesday (May 13) at the Hyatt Regency Louisville.

The Institute of Molecular Cardiology, under the leadership of Director Roberto Bolli, M.D., received the Healthcare Innovation Award and Donald Miller, M.D., Ph.D., director of the cancer center, a part of KentuckyOne Health, was named the XLerateHealth Physician of the Year.

The Healthcare Innovation Award is presented to an organization that has developed a new procedure, device, service program or treatment that improves the delivery of medical care. Under Bolli’s leadership, the Institute of Molecular Cardiology (IMC) has become recognized worldwide as a leading cardiovascular research program for its contributions in ischemic heart disease, heart failure, diabetes and obesity and adult stem cell therapy for cardiac repair and regeneration. Established in 2001, the IMC consistently brings more than $13 million annually in federal funding to the Louisville Metro region in developing novel treatments and future cures for the nation’s No. 1 killer, cardiovascular disease.

The XLerateHealth Physician of the Year Award is conferred upon a physician who has shown outstanding leadership and vision and has contributed to his or her workplace, leaving a lasting legacy. Named director of the James Graham Brown Cancer Center (JGBCC) in 1999, Miller also is the James Graham Brown Foundation Chair and Professor of Oncology and Associate Vice President for Health Affairs at UofL. Under his leadership, the JGBCC developed a nationally recognized leadership program in cancer drug development with more than two dozen novel treatments being studied and three entering early phase clinical trials. Miller’s own laboratory is currently studying short DNA sequences which are believed to cause cancer cell death; it is expected that treatments from his lab will enter clinical trials within the next two years.

Since 2007 IGE Media, publisher of Medical News and Medical News For You, has recognized excellence at the annual MediStar Awards, honoring professionals, volunteers and programs for their impact on health care. Also named finalists for MediStar Awards from UofL were:

• BOK Financial Aging Care Award: UofL Physicians-Geriatrics
• Facility Design Award: Nucleus Innovation Park Downtown and School of Dentistry and Department of Pediatrics at the Sam Swope Kosair Charities Centre
• Hall Render Leadership in Healthcare Award: Gerard Rabalais, M.D., Chair, Department of Pediatrics
• Middleton Reutlinger Nurse of the Year Award: Stephanie Jensen, R.N., Diabetes Nurse Educator, UofL Physicians-Pediatric Endocrinology
• Seven Counties Services Healthcare Advocacy Award: Stephen Wright, M.D., Professor, Department of Pediatrics
• A.O. Sullivan Award for Excellence in Education: Department of Pediatrics Medical Education Program
• XLerateHealth Physician of the Year Award: Toni Ganzel, M.D., Dean, School of Medicine

Cardiovascular disease is the leading cause of death among women, striking one in three. About every 60 seconds, a woman dies from heart disease.

With this as a backdrop, the University of Louisville School of Medicine, Department of Cardiovascular & Thoracic Surgery, in conjunction with KentuckyOne Health and University of Louisville Physicians, is hosting a one-day conference in Louisville to help educate patients and health care professionals about the prevention, recognition and treatment of the disease in women.

Heart disease is more deadly for women than all forms of cancer combined, according to the American Heart Association, and 90 percent of women have one or more risk factors, and more than one in three have some form of cardiovascular disease. Yet, women don’t recognize that heart disease is their biggest health threat.

“Although heart disease is a multi-factored, complex disorder, it is preventable, but education about the disease in women is essential,” said Kendra Grubb, M.D., assistant professor of cardiovascular and thoracic surgery at UofL.

To help in this educational effort, Grubb has organized the 2014 Louisville Symposium on Heart Disease in Women, the first of what is planned to be an annual event.

The conference will be held Saturday, June 28, at the Jewish Hospital Rudd Heart & Lung Center, 16th Floor Conference Center, 201 Abraham Flexner Way in Louisville. It is designed to provide physicians, nurses, allied health professional and the community with up-to-date information pertaining to the prevention and treatment of cardiovascular disease in women.

Two dozen doctors and health professionals are scheduled to speak including Toni Ganzel, M.D., dean of the UofL School of Medicine, and Ruth Brinkley, CEO of KentuckyOne Health.

The conference begins at 7 a.m. with registration and a continental breakfast, with the program starting at 8 a.m. The event ends at 5 p.m., with a reception to follow.

Continuing medical education (CME) credit is available. For more information on CME credit, click http://www.louisvilleheartdiseasewomen.com/about.html.

To see the agenda, click http://www.louisvilleheartdiseasewomen.com/agenda.html.

All are welcome at the conference, but registration is required. Costs are:

• Physicians: $100
• Allied health professionals/nurses: $50
• Community: $25
• Students/residents/fellows: Free with registration before June 2

To register, click http://www.louisvilleheartdiseasewomen.com/registration-contact.html.

For more about the conference, go to http://www.louisvilleheartdiseasewomen.com/home.html or call 502-561-2180.

Researchers at the University of Louisville are launching a clinical research study to develop an objective approach to discharge patients with heart failure from the hospital with the goal of decreasing their possible readmission.

Saeed A. Jortani, Ph.D., clinical associate professor of pathology and laboratory medicine, will lead a team of investigators including cardiologists, emergency medicine physicians, nurses and clinical coordinators in the “Congestive Heart Failure Readmission (CHFR) Trial.” It is now open for enrollment.

The team’s goal is to enroll 600 patients with symptoms of congestive heart failure who are admitted to the emergency departments at two KentuckyOne Health hospitals, University of Louisville Hospital and Jewish Hospital. Blood samples will be collected from patients at the time they are admitted and again when they are discharged. These samples will be analyzed for a variety of cardiac and kidney biomarkers.

The patients then will be surveyed twice, at 30 days and 6 months after discharge, to learn if their condition required readmission to the hospital.

The team will use the data obtained from the blood samples to develop an evidence-based approach that could be used in determining the optimal timing for discharging patients with heart failure and ultimately prevent readmission.

“We believe that using an objective, clinically verified approach to discharging heart failure patients initially could reduce the need for future readmission,” Jortani said. “Our thinking is that patients’ biomarkers will indicate when they are ready for discharge from the hospital with hopefully less chance of being readmitted later on.”

According to the Centers for Disease Control and Prevention, heart failure affects about 5 million people in the United States, with 550,000 new patients diagnosed each year. Patients with heart failure also have a high incidence of other life-threatening diseases and conditions, such as renal failure, hypertension, diabetes and others.

Each year, more than 1 million people are admitted to an inpatient facility for heart failure, and 27 percent of patients with heart failure who are on Medicare are readmitted within 30 days.

New guidelines established by the Affordable Care Act limits put limits on readmitting patients within a 30-day time period for the same diagnosis.

“Finding the right ‘formula’ for discharge and reducing readmission rates will help us improve the ultimate health outcome for the patient as well as realize significant cost savings in the long run,” Jortani said.

###

About the CHFR Trial:

Principal investigator of the CHFR Trial is Saeed Jortani. The research team includes cardiologists Andrew DeFilippis, Shahab Ghafghazi and Jesse Adams; emergency medicine physicians George Bosse, Salvator Vicario and Tadd Roberts; nurses Ashlee Melendez, Kristen Young and Cynthia Lawrence; clinical coordinators Stanislava Prather, Anna Mains, Keivan Hosseinnegad and Louise Isaacs; and biostatistician Richard Baumgartner. Blood sample analysis will be conducted at the Kentucky Clinical Trials Laboratory. The study is funded in part by Roche Diagnostics USA. For information about the trial, contact 502-852-8835 or sjortani@louisville.edu.

Darrell A. Griffith has been named the new associate vice president for health affairs/finance and administration for the University of Louisville Health Sciences Center. He also will assume the position of vice president/CFO for University of Louisville Physicians. Griffith comes from the University of Kentucky/UK Healthcare, where he was the executive director for the faculty practice organization.

David L. Dunn, M.D., Ph.D., UofL executive vice president for health affairs, highlighted Griffith’s extensive financial experience within academic medicine and physician practices.

“I am very pleased to welcome Darrell to the UofL Health Sciences Center,” Dunn said. “He understands the complexity of an academic health center and the role of the faculty practice plan. His experience is critical as we begin the next steps in the transformation of the health sciences center.”

Griffith has spent the past 11 years at the University of Kentucky, initially as a senior manager of business development and decision support. He served two years as the interim associate dean for administration and finance for the College of Medicine before taking his current role in 2006. He was instrumental in developing the UK Healthcare strategic plan that saw unprecedented growth in revenues and outpatient care.

Prior to joining UK, Griffith was a senior consultant with Avalon Management Consulting LLC, in Knoxville, Tenn. He also has been with Promina-Dekalb Regional Healthcare System in Atlanta, Erlanger Health System in Chattanooga, Tenn., and Healthcare Resources Inc. in Somerset, Ky.

Griffith earned his bachelor of science in business administration and his master of public health/health care administration from the University of Tennessee. He is a certified medical practice executive from the American College of Medical Practice Executives. He is a member of the Academic Practice Plan Directors under the University Health Consortium.

The singer-songwriter of 2007’s country hit “Stealing Cinderella” and the currently-rising-up-the-charts “Us Again,” Chuck Wicks, will walk the red carpet at The Julep Ball.

The premier Derby Eve Party with a Purpose, The Julep Ball is held annually on the evening before the Kentucky Derby and supports the work of the James Graham Brown Cancer Center at the University of Louisville. The event on May 2 at the KFC Yum! Center kicks off with a 6:30 p.m. cocktail reception, followed by dinner and a live auction at 8 p.m.

An Official Event of the 140^th Kentucky Derby®, The Julep Ball provides a celebrity-studded night to remember with a multi-course seated dinner, a knock-your-socks-off auction, multiple open specialty bars, complimentary valet parking, and dancing until the wee hours of Derby morning. Tickets for the full evening of entertainment are sold out but a limited number of dance-only tickets at $100 per person are still available. For further information and to buy tickets, go to The Julep Ball website, julepball.org.

About Chuck Wicks:

On his new single that is rising the charts, “Us Again,” Chuck Wicks is clearly in the zone. The story of a couple who long to return to a time when loving each other was easy, the song also marks the return to the country charts for the Delaware farm boy.

“It’s a unique love song,” says Wicks, who co-wrote the hit with Andy Dodd and Tiffany Vartanyan. “It’s one of those things we all go through. When you first meet that someone who is really special, the first three to four months are flawless. Every day is a honeymoon. But as time goes on and life starts to happen, you can forget what it’s like and lose that spark.”

Now signed to Blaster Records, Wicks, who moonlights as a morning personality on NASH-FM’s popular America’s Morning Show (“I love speaking the language of country music and this gives me the chance to do that every day,” he says), has discovered his own creative fire.

After the breakout success of his 2007 debut single “Stealing Cinderella,” which hit the Top 5 on the Billboard country chart and marked the biggest single for any new country artist in 2007, the pristine-voiced singer actively took a step back and committed himself to songwriting. Freshly inspired, he’s readying his latest album, the follow-up to 2008’s Starting Now, which peaked at No. 7 on the Billboard country albums chart.

“I’m a lot more comfortable with who I am,” he says. “I feel like I’ve figured out who I am as a songwriter, as a singer, as an artist. I know where my pocket is.”

The upcoming album, co-produced by Chuck, will include all of the tracks from his EP Rough, a recent collection of songs that showcased Chuck’s lived-in sound.

“From Starting Now to today, I’ve grown so much as a writer and a performer,” says Wicks, who has performed in every state in the continental United States. “Releasing your first single on a major label is a lot to navigate, especially if you’ve never done it. I got thrown out on a huge tour with Brad Paisley and went from playing conference rooms with two guitar players to playing Denver, Colorado, my first big show in an arena.

“Grow up, have a family and work 9 to 5: That’s what most everybody sees in their future,” Wicks says. “I feel so lucky to do something different and special.”

###

About the James Graham Brown Cancer Center:

The James Graham Brown Cancer Center is a key component of the University of Louisville Health Sciences Center. As part of the region's leading academic, research and teaching health center, the cancer center provides the latest medical advances to patients, often long before they become available in non-teaching settings. The JGBCC is a part of KentuckyOne Health and is affiliated with the Kentucky Cancer Program. It is the only cancer center in the region to use a unified approach to cancer care, with multidisciplinary teams of physicians working together to guide patients through diagnosis, treatment and recovery. For more information, visit our web site, www.browncancercenter.org.

The Julep Ball is sponsored in part by Advanced Cancer Therapeutics, Ashton Advertising, Bob Montgomery Dixie Honda, Boutique Serendipity, The Dahlem Company, Dillards, Enterprise, Headz Salon, Heaven Hill, Hubbuch & Co., InGrid Design, Jaust Consulting Partners, Jefferson County Sheriff’s Office, KentuckyOne Health, Kroger, Louisville Magazine, Maker’s Mark, Millennium: The Takeda Oncology Company, Morgan Stanley, MPI Printing, Nfocus, Old 502 Winery, Power Creative, Tito’s Handmade Vodka, WAKY and WHAS11.

Five of University of Louisville Head Coach Rick Pitino’s key assistants will walk the red carpet at The Julep Ball.

Mike Balado, Kenny Johnson, Wyking Jones,Kevin Keatts and David Padgett will be among the stars from the sports and entertainment worlds at the May 2 gala.

The premier Derby Eve Party with a Purpose, The Julep Ball is held annually on the evening before the Kentucky Derby and supports the work of the James Graham Brown Cancer Center at the University of Louisville. The event on May 2 at the KFC Yum! Center kicks off with a 6:30 p.m. cocktail reception, followed by dinner and a live auction at 8 p.m.

An Official Event of the 140^th Kentucky Derby®, The Julep Ball provides a celebrity-studded night to remember with a multi-course seated dinner, a knock-your-socks-off auction, multiple open specialty bars, complimentary valet parking, and dancing until the wee hours of Derby morning. A limited number of tickets to The Julep Ball are still available. The full evening’s entertainment is $600 per person, $5,000 for a table of 10, and $100 per person for dance-only tickets. For further information and to buy tickets, go to The Julep Ball website, julepball.org.

About Balado, Johnson, Jones, Keatts and Padgett:

Mike Balado (pronounced bah-LAW-doe) joined the University of Louisville men's basketball staff as an assistant coach in April 2013 after serving in a similar capacity at Florida International from 2012-13.

Balado helped FIU to quickly achieve success when the 18-14 Panthers produced their first winning season in 13 years, the fourth-highest win total in school history and the most Sun Belt Conference victories (11) since joining the league in 1998-99. He was an assistant under Richard Pitino, the son of UofL head coach Rick Pitino, who is now the head coach at Minnesota.

"Mike brings a wealth of experience in both the recruiting world and in coaching," said Pitino. "An important factor in adding him to our staff was his knowledge of what we do defensively and in scouting, after working with Richard (Pitino) for a year. It should not take a great deal of time in acclimating him to our program. He's a tireless worker and he should fit like a glove. He also brings another facet to our recruiting efforts, as he speaks fluent Spanish and has connections throughout Latin America."

Prior to his year at FIU, Balado worked three seasons at High Point University (2009-12), where he assisted in all areas of the Panther basketball program with a heavy concentration on recruiting. He spent the 2008-09 season on the Miami (Fla.) basketball staff where he helped the Hurricanes compile a 19-13 record and a berth in the National Invitation Tournament (NIT) while working on player development, scouting and game preparation.

Balado played collegiate basketball at St. Thomas University in Miami, where he was a two-year starter and captain while helping his team win the regular season conference title in 1997. Recipient of a student-athlete leadership award as a senior, he earned a bachelor's degree in psychology from St. Thomas in 1998 and a master's of education in exercise and sport science from Augusta State in 2000. A native of Miami, Fla.,

Balado is married to the former Alicia Nigro and the couple had twins, Aiden and Addy, in June 2009.

Kenny Johnson, assistant men's basketball coach and recruiting coordinator at Indiana for the past two years, joined the Louisville men's basketball staff as an assistant coach under head coach Rick Pitino in April 2014.

"We're very excited to have Kenny in our program," said Pitino. "The first thing I did when Kevin Keatts left to become the head coach at UNC Wilmington was to ask my son Richard (Pitino, head coach at Minnesota) to find the best rising assistant coach in the business. He spoke to a lot of people and they led directly to Kenny Johnson and others think he is outstanding as well. He is extremely bright, having studied cell, molecular biology and genetics in college."

While at Indiana, Johnson helped the Hoosiers assemble top 20 recruiting classes each of the past two seasons. On the court, Indiana produced a combined 46-22 record in his two seasons there, winning the Big Ten Championship, earning a No. 1 seed in the NCAA Tournament and reaching the NCAA Sweet 16 in 2013.

ESPN.com's Jeff Goodman, after surveying more than 200 collegiate coaches, named Johnson as the nation's 11th most respected/feared assistant coach in a July 2013 listing after just two seasons as a collegiate assistant.

Johnson was an assistant coach at Towson in 2011-12, helping assemble a top five mid-major recruiting class. He began his coaching career in 2002 as the associate head coach at Eleanor Roosevelt High School before moving to Dr. Henry Wise High School in 2006 for one year. He was associate head coach at Paul IV High school for four years (2007-11) before advancing to the collegiate ranks.

As a senior at Oxon Hill (Md.) High School in 1994, he was named Science and Technology Student of the Year. He earned his bachelor's degree in cell, molecular biology and genetics in 1999 at the University of Maryland, where he was a Benjamin Banneker Scholarship recipient. He worked as a protein chemist/molecular biologist at Human Genome Sciences in Rockville, Md. after graduation.

A native of Oxon Hill, Johnson and his wife, Doreen, have two sons, Amare (11) and Mekai (8).

Wyking Jones (pronounced WHY-king) is in his third season as an assistant basketball coach for the University of Louisville after serving in a similar capacity two seasons at the University of New Mexico. He joined the Cardinals in April 2011.

"Wyking has the experience necessary to help us recruit top-notch student-athletes from all 50 states," said Pitino. "He is highly regarded in all circles as a tireless worker and an outstanding communicator with young people. I had asked Richard (Pitino) to provide me the top five assistant coaching candidates in the country and I would interview them. Immediately he had Wyking at the top of the list. After considerable research, it was apparent that he had all of the characteristics necessary to bring to Cardinal Basketball."

In Jones' two seasons, the Cardinals reached the NCAA Final Four twice - including winning the 2013 NCAA Championship -- and have a combined 65-15 record. He has helped the Cardinals assemble two straight top 10 recruiting classes.

During Jones' two years at New Mexico under head coach Steve Alford, the Lobos produced a combined 52-18 record. The 2009-10 New Mexico team won a school-record 30 games (30-5 record), won the Mountain West Conference Championship and was ranked eighth in the final AP poll.

Before joining the New Mexico staff, Jones spent two years as a basketball travel team manager with Nike Elite Youth Basketball. There he managed all 45 travel teams and the tournaments that Nike sponsored in its grassroots youth program while he built key relationships across the nation.

Jones lettered four years at Loyola Marymount for head coach John Olive (1991-95). He emerged as a junior through a staunch work ethic and unassuming manner to earn all-West Coast Conference honors and the Lions’ Student Athlete of the Year in 1993-94.

Jones earned a bachelor's degree in business administration from Loyola Marymount in 1995. He served as a Lions' assistant coach during the 1996-97 season. He and his wife, Estrella, have a son, Jameel, and a daughter, Zoe.

Kevin Keatts, who won two national prep championships and was runner-up on three occasions as head coach at Hargrave Military Academy over eight seasons, just wrapped up his final year on the University of Louisville men's basketball staff.

In March, Keatts was named head coach at University of North Carolina-Wilmington, joining 10 other former assistants under Pitino now serving as college head coaches.

"Kevin has been one of the best assistant coaches with which I have had the good fortune to work, and I've had a lot of them," Pitino said. "He is a terrific person, coach, scout, family man and recruiter. He possesses all of the variables to build a successful program. We are really going to miss his upbeat personality … ."

Keatts was promoted to associate head coach in January 2014 after serving as an assistant coach under head coach Rick Pitino since joining the Cardinals in April 2011 and helped the Cardinals assemble two straight top ten recruiting classes. In his two seasons at UofL, the Cardinals reached the NCAA Final Four twice -- including winning the 2013 NCAA Championship -- won two Big East Conference championships, and have a combined 65-15 record.

ESPN.com's Jeff Goodman, after surveying more than 200 collegiate coaches, named Keatts as the nation's third most respected/feared assistant coach in a July 2013 listing.

Keatts' success as a prep coach is staggering. In 10 seasons in two separate stints as the head coach at Hargrave (1999-2001, 2003-2011), he compiled an incredible 263-17 record with two national prep titles (2004, 2008), three runner-up finishes (2005, 2006, 2009) and two additional appearances among the final four prep teams (2007, 2010).

Keatts coached nine players at the prep level that reached the NBA: Joe Alexander, Jordan Crawford, Josh Howard, Vernon Macklin, Mike Scott, Marreese Speights, Sam Young, David West and Korleone Young.

Keatts was a two sport standout in basketball and football at Heritage High School in Lynchburg, Va., and also excelled in basketball at Ferrum College. He and his wife Georgette have two sons, Kevin (9) and Kaden (5).

David Padgett, a former three-year starting center for the Cardinals, is in his first year on the UofL men’s basketball staff as assistant video coordinator.

Padgett spent three years as an assistant basketball coach at IUPUI (2011-14) after a year with UofL as an assistant strength coach (2010-11). He played professional basketball for UB LaPalma in the Canary Islands for two years following his graduation from UofL. He had reached the final preseason cut of the Miami Heat before his playing career in Spain.

A three-year starter and captain at center for the Cards (2005-08), Padgett was a unanimous first-team All-BIG EAST Conference selection as a senior and also earned USBWA All-District IV honors.  He averaged a team-leading 11.2 points and grabbed 4.8 rebounds his senior year in 2007-08 when the Cardinals reached the NCAA Elite Eight.

Padgett ranks second in career field goal percentage at UofL, hitting 61.3 percent of his shots (332-542). His .667 field goal percentage as a senior was the second best ever at UofL. He set a BIG EAST Conference field goal percentage record for league games as a senior, hitting 68.3 percent of his shots in 18 games (86-of-126). He was a second team All-BIG EAST pick as a junior.

Padgett’s basketball bloodlines run deep as his father played at the University of Nevada and his uncle played at New Mexico. His grandfather Jim played for Oregon State and his sister played for the University of San Diego.

Padgett and his wife, Megan, welcomed their first child Nolan in August 2013.

###

About the James Graham Brown Cancer Center:

The James Graham Brown Cancer Center is a key component of the University of Louisville Health Sciences Center. As part of the region's leading academic, research and teaching health center, the cancer center provides the latest medical advances to patients, often long before they become available in non-teaching settings. The JGBCC is a part of KentuckyOne Health and is affiliated with the Kentucky Cancer Program. It is the only cancer center in the region to use a unified approach to cancer care, with multidisciplinary teams of physicians working together to guide patients through diagnosis, treatment and recovery. For more information, visit our web site, www.browncancercenter.org.

The Julep Ball is sponsored in part by Advanced Cancer Therapeutics, Ashton Advertising, Bob Montgomery Dixie Honda, Boutique Serendipity, The Dahlem Company, Dillards, Enterprise, Headz Salon, Heaven Hill, Hubbuch & Co., InGrid Design, Jaust Consulting Partners, Jefferson County Sheriff’s Office, KentuckyOne Health, Kroger, Louisville Magazine, Maker’s Mark, Millennium: The Takeda Oncology Company, Morgan Stanley, MPI Printing, Nfocus, Old 502 Winery, Power Creative, Tito’s Handmade Vodka, WAKY and WHAS11.

Two of the hottest acts making names for themselves in country music have just been added to the lineup of performers at The Julep Ball.

The duo Brothers Osborne, who recently dropped their latest single “Rum,”and Hart of Dixie and Anger Management star Laura Bell Bundy, whose country single “Giddy On Up” garnered over 4 million streams, will join J.D. Shelburne and the Bob Hardwick Sound on The Julep Ball stage.

The premier Derby Eve Party with a Purpose, The Julep Ball is held annually on the evening before the Kentucky Derby and supports the work of the James Graham Brown Cancer Center at the University of Louisville. The event on May 2 at the KFC Yum! Center kicks off with a 6:30 p.m. cocktail reception, followed by dinner and a live auction at 8 p.m.

An Official Event of the 140^th Kentucky Derby®, The Julep Ball provides a celebrity-studded night to remember with a multi-course seated dinner, a knock-your-socks-off auction, multiple open specialty bars, complimentary valet parking, and dancing until the wee hours of Derby morning. A limited number of tickets to The Julep Ball are still available. The full evening’s entertainment is $600 per person, $5,000 for a table of 10, and $100 per person for dance-only tickets. For further information and to buy tickets, go to The Julep Ball website, julepball.org.

About Brothers Osborne:

One of 15 acts chosen by Country Weeklyas “Ones to Watch in 2014,” Brothers Osborne were chosen this month to open for Eric Church in his upcoming tour that includes a stop in Louisville at the KFC Yum! Center on Sept. 25.

The current Rolling Stone(April 24) hails the duo’s current single “Rum”: “There are plenty of drinking songs coming out of Nashville these days, but this twangy party anthem by a rising sibling duo from Maryland takes the genre to a whole new level of catchy fun. Sounds like a hit to us!”

For John and TJ Osborne, getting into music was unavoidable. Growing up in the water town of Deale, Md., their close-knit-family of seven spent most nights not in front of the television, but writing and playing songs.

John (guitar) moved to Nashville first to play in other bands before TJ (vocals/guitar) joined him. It was then they formed Brothers Osborne and began playing as many writer rounds as they could. In April 2011, Warner Chappell/King Pen Music offered them a publishing deal. A year later, Capitol Records offered them a record deal. The Brothers Osborne are currently in the studio finishing their debut album, an album they describe as “aggressive, bold and fragile at times.” For more information, visit www.brothersosborne.com.

About Laura Bell Bundy:

A Kentucky native, Laura Bell Bundy is a performer who has done it all: from appearing on the Broadway stage as Elle Woods in Legally Blonde – a role that garnered her a Tony Award nomination – Glinda in Wicked, and Amber Von Tussle in the original cast of Hairspray, to the launch of her country music career with a captivating performance on the nationally televised Academy of Country Music Awards, to acting in various film and TV roles including Dreamgirls, Jumanji, The Adventures of Huck Finn, MTV’s smash telecast of Legally Blonde, Guiding Light, CBS’s How I Met Your Mother, Malibu Country, Home Improvement and Cold Case. Bundy’s screen success has followed her to the web, where she has attracted a worldwide audience with her hit comedic web series, Cooter County, which she created, produced and directed.

Bundy released her debut country music album, Achin’ and Shakin’, in 2010, featuring her hit single “Giddy On Up,” which has since garnered over 4 million streams and has been certified gold in Norway. Her most recent singles, “Two Step” and “Kentucky Dirty,” push music boundaries and answer the question of what happens when you combine hot country, dance tracks and hip-hop beats.

Bundy currently can be seen on the CW’s hit television program Hart of Dixie and FX’s Anger Management, both of which are aired throughout the world. Her latest song release, “Kentucky Dirty” hit iTunes in November of 2013. The track references the singer’s good ole Kentucky roots. For more information, visit www.laurabellbundy.com.

About the James Graham Brown Cancer Center:

The James Graham Brown Cancer Center is a key component of the University of Louisville Health Sciences Center. As part of the region's leading academic, research and teaching health center, the cancer center provides the latest medical advances to patients, often long before they become available in non-teaching settings. The JGBCC is a part of KentuckyOne Health and is affiliated with the Kentucky Cancer Program. It is the only cancer center in the region to use a unified approach to cancer care, with multidisciplinary teams of physicians working together to guide patients through diagnosis, treatment and recovery. For more information, visit our web site, www.browncancercenter.org.

The Julep Ball is sponsored in part by Advanced Cancer Therapeutics, Ashton Advertising, Bob Montgomery Dixie Honda, Boutique Serendipity, The Dahlem Company, Dillards, Enterprise, Headz Salon, Heaven Hill, Hubbuch & Co., InGrid Design, Jaust Consulting Partners, Jefferson County Sheriff’s Office, KentuckyOne Health, Kroger, Louisville Magazine, Maker’s Mark, Millennium: The Takeda Oncology Company, Morgan Stanley, MPI Printing, Nfocus, Old 502 Winery, Power Creative, Tito’s Handmade Vodka, WAKY and WHAS11.